Want to see JP:4582 full AI Analyst Report?
4582 Stock Chart & Stats
¥64.00
¥1.00(1.52%)
At close: 4:00 PM EDT
¥64.00
¥1.00(1.52%)
Day’s Range― - ―
52-Week Range¥59.00 - ¥229.00
Previous CloseN/A
Volume398.00K
Average Volume (3M)617.67K
Market Cap
¥4.81B
Enterprise Value¥5.12K
Total Cash (Recent Filing)¥977.18M
Total Debt (Recent Filing)¥832.50M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-100.06
Shares Outstanding80,246,460
10 Day Avg. Volume422,570
30 Day Avg. Volume617,670
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginA consistently strong gross margin indicates that the company’s products retain meaningful economics before operating expenses. If revenue stabilizes and selling, research, and other costs are better controlled, this gross-profit base could support a recovery in operating performance over the next several quarters.
Specialty Pharmaceutical FocusA focus on specialty and oncology therapies gives Symbio a defined position within prescription pharmaceuticals rather than relying on a broad, undifferentiated portfolio. These areas can support focused development, regulatory expertise, and lifecycle management of approved medicines over time.
Multiple Monetization RoutesThe business model provides several potential ways to monetize pharmaceutical assets, including direct product sales and collaboration or licensing income. This structure can create opportunities to share development and commercialization economics with partners while retaining upside through royalties or profit-sharing.
Bears Say
Multi-Year Revenue DeclineSeveral consecutive years of revenue contraction, culminating in an approximately 28% decline in 2025, indicate weakening commercial scale and reduced operating leverage. Persistent top-line deterioration can limit funding for development, make fixed costs harder to absorb, and delay any return to sustainable profitability.
Deepening UnprofitabilityThe reversal from solid positive margins to deeply negative operating and net margins shows that the current revenue base is not covering the company’s broader cost structure. Even with strong gross margin, sustained operating losses can erode capital and constrain investment in future products and indications.
Cash Burn And Higher LeverageNegative operating and free cash flow mean the business is not currently funding itself from operations, while new debt and compressed equity increase financial risk. Continued losses could require further external financing, reduce flexibility for development spending, and heighten liquidity pressure if cash outflows persist.
Symbio Pharmaceuticals Limited News
4582 FAQ
What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?
Symbio Pharmaceuticals Limited lowest stock price was ¥59.00 and its highest was ¥229.00 in the past 12 months.
What is Symbio Pharmaceuticals Limited’s market cap?
Symbio Pharmaceuticals Limited’s market cap is ¥4.81B.
When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?
Symbio Pharmaceuticals Limited’s upcoming earnings report date is Oct 29, 2026 which is in 48 days.
How were Symbio Pharmaceuticals Limited’s earnings last quarter?
Symbio Pharmaceuticals Limited released its earnings results on Jul 30, 2026. The company reported -¥15 earnings per share for the quarter.
Is Symbio Pharmaceuticals Limited overvalued?
According to Wall Street analysts Symbio Pharmaceuticals Limited’s price is currently Overvalued.
Does Symbio Pharmaceuticals Limited pay dividends?
Symbio Pharmaceuticals Limited does not currently pay dividends.
What is Symbio Pharmaceuticals Limited’s EPS estimate?
Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Symbio Pharmaceuticals Limited have?
Symbio Pharmaceuticals Limited has 80,246,460 shares outstanding.
What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?
Symbio Pharmaceuticals Limited reported an EPS of -¥15 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in JP:4582
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
Technical Analysis
Solasia Pharma KK
―
Wakamoto Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Medrx Co., Ltd.
―